(S)-2,2-dimethyl-4-oxo-1,3-dioxolane-5-acetyl chloride | 174563-62-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-2,2-dimethyl-4-oxo-1,3-dioxolane-5-acetyl chloride
• 英文别名: (S)-(+)-2,2-dimethyl-5-oxo-1,3-dioxolane-4-acetic chloride；2-[(4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetyl chloride
• CAS: 174563-62-3
• 化学式: C₇H₉ClO₄
• 分子量: 192.599
• InChiKey: WIOHYYHBCRRMQJ-BYPYZUCNSA-N

物化性质

• 沸点：
  274.6±15.0 °C(Predicted)
• 密度：
  1.268±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-2,2-dimethyl-4-oxo-1,3-dioxolane-5-acetyl chloride 以 乙酸乙酯 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  子囊霉素的32-（O）-酰化和32-（O）-硫酰化的类似物的制备和免疫抑制活性。

  摘要：

  已合成了抗生素子囊霉素（1）的一系列32-（O）-酰化和32-（O）-硫酰化的衍生物。这些易得的类似物在体外表现出有效的免疫抑制活性，如通过白介素2报道基因测定和混合淋巴细胞反应所测量。预期此类分子在气道的慢性炎性疾病如哮喘中具有治疗潜力。

  DOI：

  10.1016/s0960-894x(98)00702-1
• 作为产物：
  描述：

  (S)-[2,2-二甲基-5-氧代二氧戊环-4-基]乙酸 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 生成 (S)-2,2-dimethyl-4-oxo-1,3-dioxolane-5-acetyl chloride
  参考文献：
  名称：

  子囊霉素的32-（O）-酰化和32-（O）-硫酰化的类似物的制备和免疫抑制活性。

  摘要：

  已合成了抗生素子囊霉素（1）的一系列32-（O）-酰化和32-（O）-硫酰化的衍生物。这些易得的类似物在体外表现出有效的免疫抑制活性，如通过白介素2报道基因测定和混合淋巴细胞反应所测量。预期此类分子在气道的慢性炎性疾病如哮喘中具有治疗潜力。

  DOI：

  10.1016/s0960-894x(98)00702-1

文献信息

• [EN] NITROGEN RING CONTAINING COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS CONTENANT UN CYCLE AZOTÉ POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：WEINGARTEN M DAVID

  公开号：WO2012135669A1

  公开（公告）日：2012-10-04

  The invention provides compounds, pharmaceutical compositions and methods of treatment of inflammatory disorders including a compound of Formula I, or its pharmaceutically acceptable salt, ester, pharmaceutically acceptable derivative or prodrug wherein R1, R2, R3, R4, X, Y, W, Z and Q are as defined herein.

  这项发明提供了化合物、药物组合物和治疗炎症性疾病的方法，包括式I的化合物，或其药用可接受的盐、酯、药用可接受的衍生物或前药，其中R1、R2、R3、R4、X、Y、W、Z和Q如本文所定义。
• Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and
  申请人：The Ohio State University Research Foundation

  公开号：US05504107A1

  公开（公告）日：1996-04-02

  The present invention relates to a method for synthesis of optically pure 4-alkenyl or 4-alkanyl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase. The invention further relates to the pharmaceutical use of such compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis.

  本发明涉及一种从光学纯醛合成光学纯的4-烯基或4-烷基-2-羟基四酮酸的方法。该发明还涉及将这些光学纯化合物作为有效的血小板聚集抑制剂，通过在环氧化酶水平上发挥作用。此外，该发明还涉及将这些化合物在治疗冠状动脉疾病中的药用，特别是在动脉粥样硬化的治疗和/或预防中的药用。
• Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic
  申请人：The Ohio State University Research Foundation

  公开号：US05656662A1

  公开（公告）日：1997-08-12

  The present invention relates to a method for synthesis of optically pure 4-alkenyl or 4-alkanyl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, thus making them useful in the treatment of coronary artery diseases, especially atherosclerosis, and additionally, as inhibitors of various inflammatory cytokines, making them useful in the treatment of both acute and chronic inflammation, as well in the treatment of cachexia, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis. The invention further relates to pharmaceutical compositions of the instant compounds.

  本发明涉及一种从光学纯醛合成光学纯4-烯基或4-烷基-2-羟基四氢呋喃酸的方法。本发明还涉及将这些光学纯化合物作为强效的血小板聚集抑制剂，通过作用于环氧合酶水平，从而使它们在治疗冠状动脉疾病，特别是动脉粥样硬化方面有用，并且作为各种炎症细胞因子的抑制剂，使其在急性和慢性炎症治疗，以及消耗症、类风湿性关节炎、多发性硬化症、克罗恩病和溃疡性结肠炎治疗中有用。本发明还涉及这些化合物的制药组合物。
• Organocatalytic <i>syn</i>-Aldol Reactions of Dioxanones with (<i>S</i>)-Isoserinal Hydrate: Synthesis of <scp>l</scp>-Deoxymannojirimycin and <scp>l</scp>-Deoxyidonojirimycin
  作者：Nagarjuna Palyam、Marek Majewski

  DOI：10.1021/jo900263s

  日期：2009.6.5

  We report a new protocol for synthesis of L-1-deoxymannojirimycin, L-1-deoxyidonojirimycin, and the N-isopropyl derivative of the latter compound from the readily available precursors (S)-isoserinal hydrate and 2-tert-butyl-2-methyl-1,3-dioxan-5-one. The key steps include diastereoselective proline-catalyzed syn aldol transformation and a reductive amination/cyclization.
• Practical synthesis of blepharismone, a mating inducing pheromone of Blepharisma japonicum
  作者：Hisashi Takihiro、Yoshiyuki Uruma、Yoshinosuke Usuki、Akio Miyake、Hideo Iio

  DOI：10.1016/j.tetasy.2006.09.005

  日期：2006.9

  Both enantiomers of blepharismone, a mating inducing pheromone produced by type II cells of Blepharisma japonicum, were synthesized via the Stille cross-coupling. reaction of [4-(tert-butyl-dimethyl-silanyloxy)-2-trimethylstannanyl-phenyl]-carbamic acid tert-butyl ester with an acid chloride derived from (S)- and (R)-malic acid as a key reaction. The mating inducing activity of synthetic (S)-blepharismone was as effective as that of the natural one. The enantiomer (R)-blepharismone showed no mating inducing activity. (c) 2006 Elsevier Ltd. All rights reserved.